ArticleCancer chemotherapy and pharmacology2018

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.

Junji Furuse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.